Corpus ID: 28368810

Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease.

@article{Fenton2004InhaledSP,
  title={Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease.},
  author={C. Fenton and G. Keating},
  journal={Drugs},
  year={2004},
  volume={64 17},
  pages={
          1975-96
        }
}
The salmeterol/fluticasone propionate dry powder inhaler (DPI) [Advair Diskus, Seretide Accuhaler] contains the long-acting beta2-adrenoceptor agonist salmeterol and the inhaled corticosteroid fluticasone propionate. In the US, twice-daily salmeterol/fluticasone propionate 50/250 microg is approved for use in adults with chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis, and in the EU, the twice-daily 50/500 microg dosage is approved for use in patients with severe… Expand
Population pharmacokinetics of fluticasone propionate/salmeterol using two different dry powder inhalers.
Budesonide/Formoterol Turbuhaler®
Diagnosis and management of exercise induced bronchoconstriction in athletes
Adherence to treatment in asthma and COPD patients in their doctors' assessment.
Solvent-mediated polymorphism and characterisation of inhaled pharmaceuticals
...
1
2
...